Please login to the form below
Daniel O'Day
This page shows the latest Daniel O'Day news and features for those working in and with pharma, biotech and healthcare.
Gilead Sciences supports Kigali Declaration for neglected tropical diseases
In signing the Kigali Declaration, we are reaffirming our commitment as part of our ongoing efforts to advance global health equity,” said Daniel O’Day, chairman and chief executive officer at
Latest news
-
Gilead’s Veklury receives FDA approval for non-hospitalised high-risk patients to treat COVID-19
Commenting on the approval, Daniel O’Day, chairman and chief executive officer at Gilead Sciences said: “Remdesivir has now helped to treat more than 10 million people around the world with
-
Gilead to pay $745m for three oncology programmes from Arcus Biosciences
Gilead is pursuing some of the most promising mechanisms of action in oncology today, with the aim of achieving better treatment outcomes for more patients,” said Gilead chairman and CEO Daniel
-
Gilead sales rise by 13%, buoyed by anti-COVID-19 drug Veklury
This was a very strong third quarter with continued positive momentum for both our commercial performance and our pipeline progress,” said Daniel O’Day, chairman and CEO. ... O’Day also focused on the company’s oncology drugs and said: “Our
-
Gilead’s Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit
triple-negative breast cancer and metastatic urothelial cancer, and the addition of Hepcludex to our portfolio,” said Daniel O’Day, chairman and chief executive officer, Gilead Sciences.
-
Gilead’s COVID-19 drug Veklury brought in almost $2bn in Q4
treated with the drug, according to Gilead's chief executive officer Daniel O’Day.
More from news
Approximately 1 fully matching, plus 40 partially matching documents found.
Latest Intelligence
-
As COVID-19 takes over the world, biopharma fights back
A number of clinical trials evaluating remdesivir’s efficacy in COVID-19 are currently underway in China and the US, with Gilead CEO Daniel O’Day commenting that “initial data” is ... have activity for,” added O’Day.
-
20 for 2020 – Five pharma leaders to watch in 2020
The pipeline-building deal is the largest under new Gilead chief executive Daniel O’Day, who took the helm of Gilead in March 2019, and includes a massive $3.95bn upfront,
-
The rise of real-world evidence
Having been stung by drugs that shine in RCTs but under deliver in day-to-day practice, these stakeholders want to know what effect therapies will have on people in the ... The takeover was driven by a belief that “regulatory-grade real-world evidence
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Ex-Roche CMO Sandra Horning joins Gilead’s board of directors
We are very pleased to welcome Sandra Horning to our Board of Directors,” said Daniel O’Day (pictured right), chairman and chief executive officer of Gilead Sciences.
-
AstraZeneca hires Roche’s Pascal Soriot as CEO
At Roche, Daniel O'Day, currently chief operating officer Roche Diagnostics has been appointed as Soriot's replacement as chief operating officer of Roche Pharma effective September 1, 2012. ... O'Day will be succeeded by Roland Diggelmann, currently
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- A new era for UK-Japanese scientific research relations
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- FDA issues innovative proposal to increase nonprescription drug access
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- My journey advancing the science in pulmonary hypertension
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
PMHub
McCann Health Medical Communications
We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
